HeyJaredVineeta Teotia
- Indexed articles, last 90 days
- 8
- Latest publication
- Jul 23, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Jul 6, 2026
Latest articles
NPs Safely Manage MRI in Patients With Cardiac Devices (opens the original)
Read excerpt
Electrophysiology nurse practitioners (NPs) enabled safe MRI scans among patients with congenital heart disease and cardiac implantable electronic device (CIED), including those with abandoned leads and MRI-nonconditional devices, without any adverse outcomes. “Specialized EP [electrophysiology] NP-provided peri-MRI CIED management can be a successful physician-adjacent service,” the authors wrote. The study was led by Brynn E. Dechert, MSN, CPNP, FHRS, Department of Pediatrics, University of Mi
Opioid Prescribing by Pain Specialists on the Rise (opens the original)
Read excerpt
Opioid prescribing by pain medicine specialists rose between 2010 and 2024, while prescribing by primary care physicians fell, a new study showed. However, overall prescribing, especially for long-term use, decreased sharply during that time period. "Long-term opioid prescribing decreased the most and was increasingly concentrated among pain medicine specialists, emphasizing the need for further research to understand whether reductions in opioid prescribing are balanced by providing nonpharmaco
Does Cancer Death Risk Increase After Transplantation? (opens the original)
Read excerpt
In a population-based study, the incidence of de novo cancer was associated with an increased risk for death among solid organ transplantation (SOT) recipients, with non-Hodgkin lymphoma showing the highest mortality. "[The study] findings underscore the importance of long-term cancer vigilance and heightened clinical awareness for transplant recipients, particularly for high-risk cancers such as PTLD [posttransplantation lymphoproliferative disorder]," the authors wrote. The study was led by Ch
Rituximab Noninferior to Ocrelizumab in Relapsing MS (opens the original)
Read excerpt
Rituximab was noninferior to ocrelizumab in preventing new disease activity and had a similar safety profile in patients with newly diagnosed relapsing multiple sclerosis (MS), a trial showed. “In this trial, rituximab was noninferior to ocrelizumab, on the basis of a 10-percentage-point noninferiority margin, in preventing new disease activity on MRI from 6 to 24 months after the start of treatment in newly diagnosed relapsing multiple sclerosis,” the investigators of the study wrote. The study
Abrocitinib Boosts Skin Clearance and Itch Relief in AD (opens the original)
Read excerpt
Treatment with abrocitinib led to minimal disease activity in patients with atopic dermatitis (AD), with at least 90% improvements in the Eczema Area and Severity Index score (EASI-90) and a peak pruritus numerical rating scale score of 0-1 (PP-NRS 0/1) by week 16, compared to treatment with dupilumab or placebo. "Treatment with abrocitinib in patients may provide a complete and robust response in those with moderate-to-severe AD, regardless of prior dupilumab exposure, and support the role of a
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.